SAMUEL D ISALY
CIK 1055949 · last filed 2018-01-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.94B
Companies
23
Total Filings
36
Lifetime Open-Market Net
-$250.26M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 10%+ Owner | 5,500,730 | $13.60 | $74.81M | -$40.22M | 2 | 2018-01-04 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | 1,191,000 | — | — | -$109.49M | 3 | 2017-11-27 |
| ASNS | 10%+ Owner | 19,533 | $0.08 | $1.5K | $0 | 1 | 2017-11-20 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | 0 | — | — | -$1.44M | 2 | 2017-10-05 |
| BOLD | 10%+ Owner | 4,806,638 | $1.41 | $6.78M | -$335.2K | 1 | 2017-09-11 |
| GKOS | Director | 1,628,111 | $126.81 | $206.46M | -$89.00M | 2 | 2017-08-17 |
| KALA | 10%+ Owner | 2,375,279 | $2.63 | $6.25M | $14.37M | 1 | 2017-07-27 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 3,298,516 | $64.97 | $214.30M | $0 | 1 | 2017-07-26 |
| ASND | Director | 6,149,377 | $218.06 | $1.34B | $15.00M | 1 | 2017-03-28 |
| CRVS | Director | 5,379,349 | $11.93 | $64.18M | $464.3K | 3 | 2016-06-27 |
| OTONOMY, INC. (OTIC) Delisted | Director | 1,953,300 | $0.08 | $150.4K | -$17.21M | 1 | 2015-11-24 |
| Sientra, Inc. (SIEN) Delisted | 10%+ Owner | 19,885 | $0.17 | $3.5K | -$14.36M | 1 | 2015-10-09 |
| Sierra Oncology, Inc. (DNAI) Delisted | Director | 1,725,790 | — | — | $8.93M | 1 | 2015-07-21 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 1,656,582 | $19.00 | $31.48M | $0 | 2 | 2014-08-11 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | 1,762,000 | — | — | $2.30M | 2 | 2013-01-29 |
| SUPN | 10%+ Owner | 0 | $44.41 | $0 | -$6.19M | 1 | 2012-12-19 |
| GNOM | 10%+ Owner | 2,922,141 | $48.95 | $143.05M | -$9.91M | 1 | 2012-07-13 |
| PCRX | 10%+ Owner | 2,546,100 | $22.99 | $58.53M | -$1.40M | 1 | 2012-02-29 |
| CCXI | 10%+ Owner | 908,509 | $10.22 | $9.28M | $0 | 1 | 2012-02-15 |
| AMRN | Director | 6,909,100 | $15.24 | $105.29M | -$1.72M | 1 | 2011-03-07 |
| NxStage Medical, Inc. (NXTM) Delisted | Director | 4,152,700 | — | — | -$1.67M | 2 | 2010-09-09 |
| ALBIREO PHARMA, INC. (BIOD) Delisted | Director | 1,512,892 | — | — | -$282.8K | 1 | 2009-06-11 |
| ATHERSYS, INC / NEW (ATHX) Delisted | Director | 3,448,000 | $0.01 | $46.5K | $1.91M | 2 | 2008-05-23 |
Recent Filings · Page 4 of 4
36 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-03-07 | AMRN | Sell (S) | −225,000 | -$1.72M | EDGAR |
| 2010-09-09 | NxStage Medical, Inc. (NXTM) Delisted | Sell (S) | −111,800 | -$1.87M | EDGAR |
| 2009-06-11 | ALBIREO PHARMA, INC. (BIOD) Delisted | Mixed | −653,976 | -$282.8K | EDGAR |
| 2008-08-28 | NxStage Medical, Inc. (NXTM) Delisted | Mixed | +55,400 | $194.1K | EDGAR |
| 2008-05-23 | ATHERSYS, INC / NEW (ATHX) Delisted | Mixed | +536,000 | $1.29M | EDGAR |
| 2008-05-21 | ATHERSYS, INC / NEW (ATHX) Delisted | Mixed | +260,000 | $624.0K | EDGAR |
Showing 31–36 of 36
Prev
Page 4 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.